Achalasia Microcephaly SyndromeSymptoms, Doctors, Treatments, Advances & More
Achalasia Microcephaly Syndrome Overview
Learn About Achalasia Microcephaly Syndrome
M Health Fairview Explorer Pediatric Specialty Clinic
William Dobyns is a Pediatrics specialist and a Neurologist practicing medicine in Minneapolis, Minnesota. He has been practicing medicine for over 48 years. Dr. Dobyns is rated as an Elite provider by MediFind in the treatment of Achalasia Microcephaly Syndrome. He is also highly rated in 51 other conditions, according to our data. His clinical expertise encompasses Increased Head Circumference, Lissencephaly, Cerebellar Hypoplasia, and Cortical Dysplasia. Dr. Dobyns is board certified in Clinical Genetics And Genomics: American Board Of Medical Genetics And Genomics, 1987. Dr. Dobyns is currently accepting new patients.
Heinrich Sticht practices practicing medicine in Erlangen, Germany. Mr. Sticht is rated as an Elite expert by MediFind in the treatment of Achalasia Microcephaly Syndrome. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Achalasia Microcephaly Syndrome, Microcephaly, Cytomegalovirus Infection, and Cortical Dysplasia.
Nemours Children's Hospital, Delaware
Michael Bober is a Medical Genetics provider practicing medicine in Wilmington, Delaware. Dr. Bober is rated as an Elite provider by MediFind in the treatment of Achalasia Microcephaly Syndrome. He is also highly rated in 69 other conditions, according to our data. His clinical expertise encompasses Microcephalic Osteodysplastic Primordial Dwarfism Type 2 (MOPD2), Microcephalic Osteodysplastic Primordial Dwarfism Type 1 (MOPD1), Achondroplasia, Osteotomy, and Adenoidectomy. Dr. Bober is board certified in American Board Of Medical Genetics And Genomics. Dr. Bober is currently accepting new patients.
Summary: MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the treatment-associated adverse events (AEs) and serious adverse events (SAEs). Second...
Summary: This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism/Hypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills. No current treatment for these conditions is available. A m...


